Bio-Rad Labs (BIO) Tops Q2 EPS by 39c

Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $1.61, $0.39 better than the analyst estimate of $1.22. Revenue for the quarter came in at $536.9 million versus the consensus estimate of $517.05 million.

2020 Financial Outlook

Given the uncertainties regarding the duration and impact of the COVID-19 pandemic, the company withdrew its previously issued annual guidance for 2020 on May 6, 2020. The company currently believes that the third quarter 2020 year-over-year currency-neutral sales may be flat to up 5 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c